Zacks: Brokerages Anticipate AzurRx BioPharma Inc (AZRX) Will Announce Earnings of -$0.20 Per Share

Analysts forecast that AzurRx BioPharma Inc (NASDAQ:AZRX) will report earnings per share (EPS) of ($0.20) for the current quarter, Zacks reports. Zero analysts have issued estimates for AzurRx BioPharma’s earnings, with estimates ranging from ($0.21) to ($0.19). AzurRx BioPharma reported earnings per share of ($0.28) in the same quarter last year, which would suggest a positive year-over-year growth rate of 28.6%. The company is scheduled to issue its next earnings results on Monday, November 12th.

On average, analysts expect that AzurRx BioPharma will report full year earnings of ($0.87) per share for the current year, with EPS estimates ranging from ($0.91) to ($0.81). For the next financial year, analysts forecast that the company will report earnings of ($0.66) per share, with EPS estimates ranging from ($0.74) to ($0.51). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover AzurRx BioPharma.

Several equities research analysts have commented on AZRX shares. HC Wainwright set a $8.00 price objective on AzurRx BioPharma and gave the stock a “buy” rating in a research note on Tuesday, October 16th. Oppenheimer started coverage on AzurRx BioPharma in a research note on Wednesday, October 17th. They set an “outperform” rating and a $6.00 price objective for the company. ValuEngine upgraded AzurRx BioPharma from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Finally, CIBC started coverage on AzurRx BioPharma in a research note on Wednesday, October 17th. They set an “outperform” rating and a $6.00 price objective for the company.

Large investors have recently bought and sold shares of the business. Opaleye Management Inc. acquired a new position in shares of AzurRx BioPharma during the 2nd quarter worth approximately $417,000. Ardsley Advisory Partners lifted its holdings in AzurRx BioPharma by 66.3% in the second quarter. Ardsley Advisory Partners now owns 137,197 shares of the company’s stock valued at $440,000 after acquiring an additional 54,697 shares during the last quarter. 683 Capital Management LLC acquired a new position in AzurRx BioPharma in the second quarter valued at approximately $1,284,000. Finally, Gilder Gagnon Howe & Co. LLC acquired a new position in AzurRx BioPharma in the second quarter valued at approximately $1,782,000. Institutional investors own 18.61% of the company’s stock.

NASDAQ:AZRX traded down $0.01 during trading hours on Friday, hitting $2.45. 47,747 shares of the stock were exchanged, compared to its average volume of 77,293. AzurRx BioPharma has a 52-week low of $2.10 and a 52-week high of $4.08.

About AzurRx BioPharma

AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.

See Also: What strategies should day traders use to execute a trade?

Get a free copy of the Zacks research report on AzurRx BioPharma (AZRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AzurRx BioPharma (NASDAQ:AZRX)

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply